Sophie J Donoghue, Mark G Williams, Eleanor G Burden, Jamie East, Timothy J Batten, Eleanor Pearce, Jonathan P Evans, Christopher D Smith
{"title":"Long-term outcomes of Grammont style reverse shoulder arthroplasty at a minimum of 10-year follow-up: A survival analysis.","authors":"Sophie J Donoghue, Mark G Williams, Eleanor G Burden, Jamie East, Timothy J Batten, Eleanor Pearce, Jonathan P Evans, Christopher D Smith","doi":"10.1177/17585732251331474","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Reverse shoulder arthroplasty (RSA) is an established and successful treatment for rotator cuff tear arthropathy. Despite increased popularity, there is a paucity of long-term survivorship data and patient-reported outcome measures. This study aimed to establish the survival at a minimum 10-year follow-up for a Grammont-style reverse shoulder prosthesis.</p><p><strong>Methods: </strong>A single centre, retrospective case series of 101 primary RSAs in 86 patients, performed between 1999 and 2012 was conducted. The primary outcome measure was all-cause revision. Implant survivorship analysis using the Kaplan-Meier method was conducted. Deaths were censored. Secondary outcomes included up-to-date Oxford Shoulder Score (OSS) in surviving patients, historic OSS scores over time and radiological outcomes.</p><p><strong>Results: </strong>Mean age was 76 years (SD ± 7.29) at time of surgery. The 10-year implant survival was 93.2% (95% confidence interval [CI] 87.8-98.6). The mean OSS was 33 (range 17-48, 95% CI 29.1-36.9) with a minimum of 10-year follow-up (<i>n</i> = 21). Radiographic review showed scapular notching in 79% of implants over 10 years old, but no radiolucency around humeral implants.</p><p><strong>Conclusions: </strong>The rate of RSA survivorship is high at 93.2% at 10 years. Most patients died with their primary implant <i>in-situ</i>. Functional outcome scores were less predictable over time.</p>","PeriodicalId":36705,"journal":{"name":"Shoulder and Elbow","volume":" ","pages":"17585732251331474"},"PeriodicalIF":1.5000,"publicationDate":"2025-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12008158/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Shoulder and Elbow","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/17585732251331474","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ORTHOPEDICS","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Reverse shoulder arthroplasty (RSA) is an established and successful treatment for rotator cuff tear arthropathy. Despite increased popularity, there is a paucity of long-term survivorship data and patient-reported outcome measures. This study aimed to establish the survival at a minimum 10-year follow-up for a Grammont-style reverse shoulder prosthesis.
Methods: A single centre, retrospective case series of 101 primary RSAs in 86 patients, performed between 1999 and 2012 was conducted. The primary outcome measure was all-cause revision. Implant survivorship analysis using the Kaplan-Meier method was conducted. Deaths were censored. Secondary outcomes included up-to-date Oxford Shoulder Score (OSS) in surviving patients, historic OSS scores over time and radiological outcomes.
Results: Mean age was 76 years (SD ± 7.29) at time of surgery. The 10-year implant survival was 93.2% (95% confidence interval [CI] 87.8-98.6). The mean OSS was 33 (range 17-48, 95% CI 29.1-36.9) with a minimum of 10-year follow-up (n = 21). Radiographic review showed scapular notching in 79% of implants over 10 years old, but no radiolucency around humeral implants.
Conclusions: The rate of RSA survivorship is high at 93.2% at 10 years. Most patients died with their primary implant in-situ. Functional outcome scores were less predictable over time.